Hua W, Mond H G, Strathmore N
Department of Cardiology, Royal Melbourne Hospital, Australia.
Pacing Clin Electrophysiol. 1997 Jan;20(1 Pt 1):17-24. doi: 10.1111/j.1540-8159.1997.tb04807.x.
It is generally believed that atrial pacing leads have higher stimulation thresholds and long-term complication rates than ventricular leads, and this is one of the factors limiting the use of dual chamber pacing. A study was undertaken to compare atrial and ventricular bipolar tined steroid-eluting leads in two designs: the Medtronic CapSure SP and the Telectronics Encor Dec. There were 123 pairs of leads: 81 CapSure SP and 42 Encor Dec. Bipolar atrial and ventricular stimulation thresholds, electrograms, and pacing impedance were measured using the Telectronics META DDDR pulse generator immediately postimplantation, and at 1, 3, and 6 months for all leads and at 12, 18, and 24 months for the CapSure SP. The only major lead complication was a 2% atrial lead dislodgment rate. All leads demonstrated low stimulation thresholds, with the CapSure SP leads having lower values than comparable Encor Dec leads. All leads had a mean range of 0.53-0.89 V at all testing periods with P < 0.05 for atrial leads only. There were no differences in electrogram size between manufacturers and no instances of atrial and ventricular undersensing. Pacing impedance was about 100 omega higher for the Encor Dec leads (P < 0.05, atrial leads only), suggesting that these leads will result in lower pacing energy losses provided the pulse generators are at identical settings. More than 90% of patients could be paced chronically in the atrium and ventricle at 2.5 V, but for chronic 1.6-V pacing, the CapSure SP leads were superior. In conclusion, atrial and ventricular steroid-eluting leads of both manufacturers gave excellent stimulation threshold results allowing low energy dual chamber pacing.
一般认为,心房起搏导线比心室导线具有更高的刺激阈值和长期并发症发生率,这是限制双腔起搏应用的因素之一。开展了一项研究,比较两种设计的心房和心室双极翼状类固醇洗脱导线:美敦力CapSure SP和泰利特Encor Dec。共有123对导线:81对CapSure SP和42对Encor Dec。使用泰利特META DDDR脉冲发生器在植入后即刻、所有导线在1、3和6个月时以及CapSure SP导线在12、18和24个月时测量双极心房和心室刺激阈值、心电图以及起搏阻抗。唯一主要的导线并发症是2%的心房导线脱位率。所有导线均显示出低刺激阈值,CapSure SP导线的值低于可比的Encor Dec导线。在所有测试期间,所有导线的平均范围为0.53 - 0.89V,仅心房导线P < 0.05。不同制造商之间的心电图大小无差异,也没有心房和心室感知不足的情况。Encor Dec导线的起搏阻抗高约100Ω(仅心房导线P < 0.05),这表明如果脉冲发生器设置相同,这些导线将导致更低的起搏能量损耗。超过90%的患者在心房和心室以2.5V可进行长期起搏,但对于慢性1.6V起搏,CapSure SP导线更优。总之,两个制造商的心房和心室类固醇洗脱导线均给出了出色的刺激阈值结果,允许进行低能量双腔起搏。